Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bristol Up As New Therapy’s Phase-3 Trial In Lymphoma Is Positive

Published 2021-06-10, 01:22 p/m
Updated 2021-06-10, 01:22 p/m
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – Bristol-Myers Squibb (NYSE:BMY) shares were up more than 3% Friday as the company’s phase-3 trial of a therapy to treat lymphoma revealed positive results.

Bristol Myers said it’s the first time a treatment beyond chemotherapy and stem cell transplant has demonstrated a benefit in relapsed or refractory large B-cell lymphoma.

Hematopoietic stem cell transplant is considered a gold standard treatment for these patients.

Breyanzi, a cell therapy, was approved by the U.S. Food and Drug Administration in February to treat adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

The company will complete an evaluation of the data and share the results with the health authorities as well as at an upcoming medical conference.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.